Pulmatrix, Inc. (NASDAQ:PULM) Sees Large Growth in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 47,700 shares, an increase of 20.8% from the December 31st total of 39,500 shares. Based on an average daily volume of 463,900 shares, the short-interest ratio is presently 0.1 days. Currently, 1.3% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Pulmatrix in a report on Sunday, January 5th. They issued a “hold” rating on the stock.

Pulmatrix Price Performance

Pulmatrix stock traded down $0.20 during midday trading on Monday, hitting $7.50. 38,164 shares of the company were exchanged, compared to its average volume of 39,441. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44. The company has a market cap of $27.38 million, a PE ratio of -2.84 and a beta of 1.61. The company’s fifty day moving average price is $6.43 and its 200-day moving average price is $3.85.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Friday, November 8th. The biotechnology company reported ($0.71) EPS for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%. The business had revenue of $0.37 million during the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.